The Cancer Letter

Inside information on cancer research and drug development

In Brief

Pfizer’s Albert Bourla to receive the AACR Outstanding Achievement Award for Service to Cancer Science and Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Albert Bourla, Pfizer’s chairman and CEO, will receive the 2024 the American Association for Cancer Research Outstanding Achievement Award for Service to Cancer Science and Medicine during the AACR Annual Meeting 2024, to be held April 5-10 in San Diego, California. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
By McKenzie Prillaman
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account